Close menu




September 17th, 2020 | 06:00 CEST

Almonty, BYD, Royal Helium - developments of great importance

  • Investments
Photo credits: pixabay.com

We live in a global business environment, though currently we seem detached due to the fight against the Corona Pandemic, business goes on and this too shall pass. Elon Musk is already preparing for the conquest of space with SpaceX and the fierce battle for market share in the automotive sector continues. Raw materials are a key component of the manufacturing industry. Therefore those who can secure access to rare raw materials often gain a decisive competitive advantage. These raw materials can also come in the form of gases and are of crucial importance, especially if they are irreplaceable and cannot be produced artificially.

time to read: 2 minutes | Author: Mario Hose
ISIN: CNE100000296 , CA0203981034 , CA78029U2056

Table of contents:


    ALMONTY INDUSTRIES INC - Access to critical raw materials

    Tungsten is one of the hardest materials on earth. The use of this metal is diverse and often significant. In the past, probably the best known use of tungsten was as a filament in light bulbs. Nowadays the raw material is very often used in the production of alloys. But tungsten is also used in the production of electronic components. Due to its special hardness, components and products made of tungsten are used in the military and aerospace industries.

    The EU has classified tungsten as a critical raw material. Anyone who has access to this raw material in legally secure regions can count on state support. Almonty is one company that benefits from this advantage, because the company owns the Sangdong Mine in South Korea, where the worlds largest tungsten deposits are believed to be found. To enable the company to press ahead with the extraction of the raw material, the German Kreditanstalt für Wiederaufbau (KfW) has committed a senior project financing loan of USD 76 million. First Berlin analysts, recommend Almonty stock as a 'buy' with a target price of CAD 1.45.

    BYD CO LTD - Internal combustion engines save the fiscal year

    In Europe, the Chinese car manufacturer BYD is regarded by investors as a trend indicator for the industry in Asia. The company sells electric vehicles, but also offers those with traditional internal combustion engines. In the first eight months of 2019, BYD sold a total of 295,066 vehicles. Due to the corona pandemic and the reduction of government subsidies for electric vehicles, sales in the same period in 2020 fell by 23.14% to only 226,792 vehicles.

    Sales of plug-in hybrid vehicles fell sharply by 66.2% from 56,572 to 19,122. Sales of SUVs with internal combustion engines increased significantly by 116.3% from 47,157 to 102,002 vehicles. The bottom line is that sales of electric vehicles have halved in the first eight months of 2020 and sales of internal combustion engines have increased by 16.9%. BYD's market capitalization has risen to over EUR 9.6 billion in the past few days. Those who have already invested for 12 months have more than doubled their investment.

    ROYAL HELIUM LTD - many customers, little competition

    The Canadian company Royal Helium focuses on the extraction of the noble gas, helium. The gas cannot be produced artificially and it is usually extracted from underground deposits. Royal Helium has access to around 400,000 hectares of licenses for the noble gas in North America, making it one of the largest market players. The helium market is a niche market and anyone wishing to invest in a company in this sector does not have much choice.

    With growing demand in the healthcare sector and in manufacturing, additional demand is coming from the aerospace industry. The US space agency NASA is already the largest consumer of the noble gas. Given that Elon Musk is forging major space plans with SpaceX, the demand for helium is likely to increase further. In Great Britain, the company 'Hybrid Air Vehicles' is already a major customer for the noble gas. The company developed the Airlander, the largest aircraft in the world that uses helium. In a few years, several hundred of these aircraft are expected to be in service worldwide.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read